Dynavax Technologies Corporation (0IDA.L)
USD 10.48
(-2.83%)
USD 10.48
(-2.83%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 232.28 Million USD | -67.86% |
| 2022 | 722.68 Million USD | 64.45% |
| 2021 | 439.44 Million USD | 844.0% |
| 2020 | 46.55 Million USD | 32.18% |
| 2019 | 35.21 Million USD | 329.6% |
| 2018 | 8.19 Million USD | 2407.03% |
| 2017 | 327 Thousand USD | -97.04% |
| 2016 | 11.04 Million USD | 172.67% |
| 2015 | 4.05 Million USD | -63.29% |
| 2014 | 11.03 Million USD | -1.95% |
| 2013 | 11.25 Million USD | 15.82% |
| 2012 | 9.71 Million USD | -55.06% |
| 2011 | 21.61 Million USD | -9.75% |
| 2010 | 23.95 Million USD | -40.6% |
| 2009 | 40.31 Million USD | 8.69% |
| 2008 | 37.09 Million USD | 163.21% |
| 2007 | 14.09 Million USD | 190.76% |
| 2006 | 4.84 Million USD | -66.93% |
| 2005 | 14.65 Million USD | -1.06% |
| 2004 | 14.81 Million USD | 1693.22% |
| 2003 | 826 Thousand USD | -42.12% |
| 2002 | 1.42 Million USD | -39.51% |
| 2001 | 2.35 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 73.79 Million USD | 45.29% |
| 2024 Q1 | 50.79 Million USD | -8.64% |
| 2023 Q4 | 55.59 Million USD | -20.02% |
| 2023 Q3 | 69.51 Million USD | 15.38% |
| 2023 Q2 | 60.24 Million USD | 28.39% |
| 2023 Q1 | 46.92 Million USD | -74.57% |
| 2023 FY | 232.28 Million USD | -67.86% |
| 2022 FY | 722.68 Million USD | 64.45% |
| 2022 Q4 | 184.49 Million USD | 9.99% |
| 2022 Q1 | 113.99 Million USD | -41.56% |
| 2022 Q2 | 256.46 Million USD | 124.98% |
| 2022 Q3 | 167.73 Million USD | -34.6% |
| 2021 Q4 | 195.07 Million USD | 80.17% |
| 2021 Q1 | 83.33 Million USD | 326.27% |
| 2021 Q2 | 52.76 Million USD | -36.68% |
| 2021 Q3 | 108.27 Million USD | 105.19% |
| 2021 FY | 439.44 Million USD | 844.0% |
| 2020 Q4 | 19.55 Million USD | 45.74% |
| 2020 FY | 46.55 Million USD | 32.18% |
| 2020 Q3 | 13.41 Million USD | 402.77% |
| 2020 Q1 | 10.91 Million USD | 3.3% |
| 2020 Q2 | 2.66 Million USD | -75.57% |
| 2019 Q2 | 8.3 Million USD | 43.79% |
| 2019 FY | 35.21 Million USD | 329.6% |
| 2019 Q1 | 5.77 Million USD | 8.56% |
| 2019 Q3 | 10.57 Million USD | 27.39% |
| 2019 Q4 | 10.57 Million USD | -0.05% |
| 2018 Q3 | 1.46 Million USD | 16.51% |
| 2018 FY | 8.19 Million USD | 2407.03% |
| 2018 Q4 | 5.31 Million USD | 264.0% |
| 2018 Q1 | 165 Thousand USD | 685.71% |
| 2018 Q2 | 1.25 Million USD | 660.0% |
| 2017 Q4 | 21 Thousand USD | -60.38% |
| 2017 Q2 | 105 Thousand USD | -29.05% |
| 2017 Q3 | 53 Thousand USD | -49.52% |
| 2017 Q1 | 148 Thousand USD | -97.97% |
| 2017 FY | 327 Thousand USD | -97.04% |
| 2016 Q4 | 7.29 Million USD | 4401.23% |
| 2016 Q2 | 2.64 Million USD | 181.0% |
| 2016 Q1 | 942 Thousand USD | 37.52% |
| 2016 FY | 11.04 Million USD | 172.67% |
| 2016 Q3 | 162 Thousand USD | -93.88% |
| 2015 Q4 | 685 Thousand USD | -42.34% |
| 2015 Q3 | 1.18 Million USD | -23.35% |
| 2015 FY | 4.05 Million USD | -63.29% |
| 2015 Q2 | 1.55 Million USD | 147.21% |
| 2015 Q1 | 627 Thousand USD | -72.46% |
| 2014 Q1 | 3.49 Million USD | 22.87% |
| 2014 FY | 11.03 Million USD | -1.95% |
| 2014 Q2 | 3.04 Million USD | -12.86% |
| 2014 Q4 | 2.27 Million USD | 3.08% |
| 2014 Q3 | 2.2 Million USD | -27.53% |
| 2013 Q2 | 3.39 Million USD | 62.69% |
| 2013 Q4 | 2.84 Million USD | -2.73% |
| 2013 FY | 11.25 Million USD | 15.82% |
| 2013 Q3 | 2.92 Million USD | -13.71% |
| 2013 Q1 | 2.08 Million USD | 15.45% |
| 2012 FY | 9.71 Million USD | -55.06% |
| 2012 Q1 | 2.35 Million USD | -79.43% |
| 2012 Q2 | 2.68 Million USD | 14.21% |
| 2012 Q3 | 2.87 Million USD | 7.08% |
| 2012 Q4 | 1.8 Million USD | -37.16% |
| 2011 Q4 | 11.42 Million USD | 873.34% |
| 2011 Q3 | 1.17 Million USD | -83.85% |
| 2011 Q2 | 7.26 Million USD | 316.8% |
| 2011 Q1 | 1.74 Million USD | -1.25% |
| 2011 FY | 21.61 Million USD | -9.75% |
| 2010 Q2 | 2.19 Million USD | -73.74% |
| 2010 FY | 23.95 Million USD | -40.6% |
| 2010 Q4 | 1.76 Million USD | -84.84% |
| 2010 Q3 | 11.64 Million USD | 431.68% |
| 2010 Q1 | 8.34 Million USD | 281.18% |
| 2009 FY | 40.31 Million USD | 8.69% |
| 2009 Q1 | 19.34 Million USD | 61.94% |
| 2009 Q2 | 15.88 Million USD | -17.89% |
| 2009 Q3 | 2.9 Million USD | -81.74% |
| 2009 Q4 | 2.18 Million USD | -24.54% |
| 2008 FY | 37.09 Million USD | 163.21% |
| 2008 Q4 | 11.94 Million USD | 34.87% |
| 2008 Q3 | 8.85 Million USD | -11.23% |
| 2008 Q2 | 9.97 Million USD | 58.03% |
| 2008 Q1 | 6.31 Million USD | -32.07% |
| 2007 Q2 | 1.8 Million USD | -9.27% |
| 2007 Q1 | 1.98 Million USD | -18.62% |
| 2007 Q3 | 1.01 Million USD | -43.67% |
| 2007 Q4 | 9.29 Million USD | 816.67% |
| 2007 FY | 14.09 Million USD | 190.76% |
| 2006 Q4 | 2.43 Million USD | 53.14% |
| 2006 FY | 4.84 Million USD | -66.93% |
| 2006 Q1 | 288 Thousand USD | -52.0% |
| 2006 Q3 | 1.59 Million USD | 200.95% |
| 2006 Q2 | 529 Thousand USD | 83.68% |
| 2005 Q1 | 12.69 Million USD | 417.23% |
| 2005 FY | 14.65 Million USD | -1.06% |
| 2005 Q4 | 600 Thousand USD | 48.51% |
| 2005 Q3 | 404 Thousand USD | -57.61% |
| 2005 Q2 | 953 Thousand USD | -92.49% |
| 2004 Q4 | 2.45 Million USD | -32.92% |
| 2004 FY | 14.81 Million USD | 1693.22% |
| 2004 Q3 | 3.66 Million USD | -33.36% |
| 2004 Q2 | 5.49 Million USD | 71.36% |
| 2004 Q1 | 3.2 Million USD | 353.32% |
| 2003 FY | 826 Thousand USD | -42.12% |
| 2003 Q4 | 707 Thousand USD | 2973.91% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | 96 Thousand USD | 0.0% |
| 2003 Q3 | 23 Thousand USD | -76.04% |
| 2002 FY | 1.42 Million USD | -39.51% |
| 2001 FY | 2.35 Million USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.458% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -765.988% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -2609.483% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -1007.802% |
| uniQure N.V. | 15.84 Million USD | -1366.162% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 41.835% |
| bluebird bio, Inc. | 29.49 Million USD | -687.483% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | 78.12 Million USD | -197.331% |
| Illumina, Inc. | 4.5 Billion USD | 94.843% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -19436.081% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 98.45% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 93.868% |
| Myriad Genetics, Inc. | 678.4 Million USD | 65.76% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 87.691% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 81.318% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 61.765% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.843% |
| Waters Corporation | 2.95 Billion USD | 92.143% |
| Biogen Inc. | 9.83 Billion USD | 97.638% |
| Nektar Therapeutics | 90.12 Million USD | -157.744% |
| Perrigo Company plc | 4.65 Billion USD | 95.011% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -82.837% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 90.398% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -31.806% |
| Evolus, Inc. | 202.08 Million USD | -14.944% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -643.333% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 98.229% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -99.67% |
| FibroGen, Inc. | 147.75 Million USD | -57.212% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 96.601% |
| OPKO Health, Inc. | 863.49 Million USD | 73.1% |
| Homology Medicines, Inc. | -6.65 Million USD | 3592.467% |
| Geron Corporation | 237 Thousand USD | -97910.127% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 87.295% |
| Exelixis, Inc. | 1.83 Billion USD | 87.308% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -540.342% |
| Zoetis Inc. | 8.54 Billion USD | 97.281% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 14.16% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -6536.686% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 97.646% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 70.509% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 51.846% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 71.989% |
| Blueprint Medicines Corporation | 249.38 Million USD | 6.855% |
| Insmed Incorporated | 305.2 Million USD | 23.893% |
| TG Therapeutics, Inc. | 233.66 Million USD | 0.59% |
| Incyte Corporation | 3.69 Billion USD | 93.715% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 77.863% |